Login / Signup

Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.

Ki Young HuhHyewon ChungYu Kyong KimSeungHwan LeeSiddharth BhatiaYohei TakanamiRyou NakayaKyung-Sang Yu
Published in: British journal of clinical pharmacology (2021)
The systemic exposure of bismuth was similar between vonoprazan- and lansoprazole-containing quadruple therapy. Vonoprazan-containing quadruple therapy was safe and well tolerated.
Keyphrases
  • helicobacter pylori
  • helicobacter pylori infection
  • mesenchymal stem cells
  • smoking cessation